SequelSEC

Regenerative Medical Technology Group Inc. RMTG

Retail-Retail Stores, NEC · CIK 0001760026 · Fiscal year ends 1231

Revenue
$5.10M
Fiscal year ended 2025-12-31
Operating income
-$867.16K
Fiscal year ended 2025-12-31
Free cash flow
-$1.31M
Fiscal year ended 2025-12-31

Regenerative Medical Technology Group Inc. (RMTG) reported revenue of $5.10M and net income of -$7.81M for the fiscal year ended 2025-12-31. This page shows 9 annual periods of income statement, balance sheet and cash flow figures normalized from Regenerative Medical Technology Group Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Retail-Retail Stores, NEC.

Income

Regenerative Medical Technology Group Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Revenue$5.10M$4.11M$2.41M$1.53M$437.89K$55.08K$30.10K$50.12K$29.24K
Cost of revenue$2.29M$1.28M$734.28K$653.26K$287.75K$43.95K$55.52K$68.33K$4.81K
Gross profit$2.81M$2.82M$1.68M$876.97K$150.14K$11.13K-$25.42K-$18.22K$24.43K
Operating income-$867.16K$81.18K-$715.23KUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net income-$7.81M-$5.56M-$9.81M-$5.51M-$12.88M-$5.90M-$2.51M-$2.06M-$377.01K
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 12.63Mshares 12.53Mshares 12.45Mshares 12.22Mshares 11.48MUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense-$1.64M-$1.16M-$2.06M-$1.16M-$2.71MUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.62$-0.44$-0.79$-0.45$-1.12UnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailable$8.20MUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$1.12M$798.32K$752.53K$424.26K$149.37K$29.87K$31.36K$43.06K$91.98K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Regenerative Medical Technology Group Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Cash & equivalents$956.72K$1.17M$530.54K$1.65M$2.98M$42.53K$23.38K$30.83K$7.75K
Total assets$4.49M$3.82M$2.88M$8.08M$9.31M$219.73K$26.38K$34.63K$7.86K
Current assets$1.22M$1.25M$575.00K$1.69M$3.02M$42.53K$23.38K$30.83K$7.86K
Total liabilities$40.54M$31.18M$24.67M$20.06M$16.06M$6.55M$7.30M$4.57M$2.57M
Current liabilities$38.13M$28.97M$22.25M$12.00M$4.22M$914.48K$6.97M$4.57M$2.57M
Total equity incl. NCI-$36.05M-$27.36M-$21.80M-$11.98M-$6.76M-$6.41M-$7.36M-$4.54M-$2.56M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$159.28K$10.12KUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$43.82K$22.60K$23.96K$49.77K$17.26KUnavailableUnavailableUnavailableUnavailable
Goodwill$1.68M$1.68M$1.68M$5.81M$5.81MUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailable$1.27M$421.33K$245.46K$181.44K$375.79KUnavailableUnavailableUnavailable

Cash flow

Regenerative Medical Technology Group Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Operating cash flow-$706.52K$850.70K-$419.20K-$1.11M-$9.88M-$322.74K-$362.32K-$244.64K-$6.12K
Capital expenditures$602.58K$215.42K$385.60K$198.43KUnavailableUnavailableUnavailable$4.00KUnavailable
Investing cash flow-$602.58K-$215.42K-$385.60K-$198.43K$666.47K-$175.00KUnavailable-$4.00K$5
Financing cash flow$1.10MUnavailable-$309.85K-$20.78K$12.15M$516.90K$354.87K$271.72K$7.21K
Net change in cashUnavailableUnavailableUnavailable-$1.33M$2.94M$19.16K-$7.46K$23.08K$1.10K
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$1.16MUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$281.07K$220.56K$310.10K$152.74K$40.86K$800$800$200Unavailable

Derived

Regenerative Medical Technology Group Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Free cash flow-$1.31M$635.28K-$804.80K-$1.31MUnavailableUnavailableUnavailable-$248.64KUnavailable
Gross margin55.1%68.7%69.5%57.3%34.3%20.2%-84.4%-36.4%83.6%
Operating margin-17.0%2.0%-29.7%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF margin-25.7%15.5%-33.4%-85.8%UnavailableUnavailableUnavailable-496.1%Unavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable3864.6%UnavailableUnavailable
Current ratio0.03x0.04x0.03x0.14x0.72x0.05x0.00x0.01x0.00x
Revenue YoY growth24.2%70.4%57.5%249.5%695.0%83.0%-39.9%71.4%Unavailable
Net margin-153.2%-135.4%-407.2%-359.9%-2942.4%-10703.5%-8335.2%-4105.6%-1289.3%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenue11.8%5.2%16.0%13.0%UnavailableUnavailableUnavailable8.0%Unavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RMTG in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-19View SEC filing
10-Q · Filed 2026-06-09View SEC filing
10-K · Filed 2026-05-14View SEC filing
10-Q · Filed 2025-11-19View SEC filing
10-Q · Filed 2025-08-19View SEC filing
10-Q · Filed 2025-05-20View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.